[go: up one dir, main page]

PT3488007T - Métodos escaláveis de recuperação elevada para produzir vetor viral adenoassociado recombinante (raav) de alto rendimento e vetores virais adenoassociados recombinantes (raav) produzidos pelos mesmos - Google Patents

Métodos escaláveis de recuperação elevada para produzir vetor viral adenoassociado recombinante (raav) de alto rendimento e vetores virais adenoassociados recombinantes (raav) produzidos pelos mesmos

Info

Publication number
PT3488007T
PT3488007T PT178319562T PT17831956T PT3488007T PT 3488007 T PT3488007 T PT 3488007T PT 178319562 T PT178319562 T PT 178319562T PT 17831956 T PT17831956 T PT 17831956T PT 3488007 T PT3488007 T PT 3488007T
Authority
PT
Portugal
Prior art keywords
raav
associated viral
recombinant adeno
vector
recovery methods
Prior art date
Application number
PT178319562T
Other languages
English (en)
Original Assignee
Spark Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60992897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3488007(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Spark Therapeutics Inc filed Critical Spark Therapeutics Inc
Publication of PT3488007T publication Critical patent/PT3488007T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT178319562T 2016-07-21 2017-07-21 Métodos escaláveis de recuperação elevada para produzir vetor viral adenoassociado recombinante (raav) de alto rendimento e vetores virais adenoassociados recombinantes (raav) produzidos pelos mesmos PT3488007T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662365312P 2016-07-21 2016-07-21

Publications (1)

Publication Number Publication Date
PT3488007T true PT3488007T (pt) 2024-03-14

Family

ID=60992897

Family Applications (1)

Application Number Title Priority Date Filing Date
PT178319562T PT3488007T (pt) 2016-07-21 2017-07-21 Métodos escaláveis de recuperação elevada para produzir vetor viral adenoassociado recombinante (raav) de alto rendimento e vetores virais adenoassociados recombinantes (raav) produzidos pelos mesmos

Country Status (19)

Country Link
US (1) US20190284576A1 (pt)
EP (1) EP3488007B1 (pt)
JP (1) JP7153009B2 (pt)
KR (3) KR102695908B1 (pt)
CN (1) CN109790549A (pt)
AU (1) AU2017299779B2 (pt)
BR (1) BR112019001146A2 (pt)
CA (1) CA3031095A1 (pt)
DK (1) DK3488007T3 (pt)
ES (1) ES2972859T3 (pt)
FI (1) FI3488007T3 (pt)
IL (2) IL301963A (pt)
MX (1) MX2019000882A (pt)
MY (1) MY194198A (pt)
NZ (1) NZ750016A (pt)
PT (1) PT3488007T (pt)
RU (1) RU2768045C2 (pt)
SG (1) SG11201900366QA (pt)
WO (1) WO2018017956A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7064214B2 (ja) 2015-09-28 2022-05-10 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 抗体回避性ウイルスベクターのための方法および組成物
EP3510161A4 (en) 2016-08-23 2020-04-22 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON
EP3773743A1 (en) 2018-04-03 2021-02-17 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
AU2019247748A1 (en) 2018-04-03 2020-10-08 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
US12091435B2 (en) 2018-04-03 2024-09-17 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
CA3133453A1 (en) 2019-03-21 2020-09-24 Daniel Mccoy Recombinant adeno-associated virus vectors
PL3953483T3 (pl) * 2019-04-11 2024-04-22 Regenxbio Inc. Sposoby chromatografii wykluczania do charakteryzowania kompozycji rekombinowanych wirusów towarzyszących adenowirusom
CN110499287B (zh) * 2019-08-30 2021-07-23 博雅干细胞科技有限公司 简易制备胎盘间充质干细胞外泌体的方法
AU2020367532A1 (en) 2019-10-17 2022-05-12 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
KR102167829B1 (ko) * 2020-02-10 2020-10-20 주식회사 이노테라피 아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법
WO2021168362A1 (en) 2020-02-21 2021-08-26 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
SI3919613T1 (sl) * 2020-06-05 2024-10-30 Sartorius Bia Separations D.O.O. Izboljšana izolacija adeno-asociiranega virusa za učinkovitejše odstranjevanje kontaminirane dna
KR20230068444A (ko) 2020-08-19 2023-05-17 사렙타 쎄러퓨틱스 인코퍼레이티드 레트 증후군의 치료를 위한 아데노 관련 바이러스 벡터
CN116529389A (zh) * 2020-08-20 2023-08-01 贝克顿迪金森公司 用于从血培养物中分离细菌的血细胞裂解剂
WO2023085382A1 (ja) * 2021-11-12 2023-05-19 Ａｇｃ株式会社 ウイルスの精製方法
JP2023141423A (ja) * 2022-03-24 2023-10-05 国立大学法人 東京大学 ウイルスの精製方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1506287E (pt) 2002-05-14 2007-07-17 Merck & Co Inc Métodos de purificação de adenovírus
EP3290513B1 (en) * 2004-06-01 2022-09-07 Genzyme Corporation Compositions and methods to prevent aav vector aggregation
TW200634145A (en) * 2005-01-25 2006-10-01 Wyeth Res Ireland Ltd Shear protectants in harvest microfiltration
FR2884255B1 (fr) * 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
BRPI0908474A2 (pt) * 2008-02-12 2016-07-26 Sanofi Pasteur Ltd métodos de uso de cromatografia de troca de íon e de filtração de gel para purificação de vírus causador da catapora
RU2547587C2 (ru) * 2008-09-24 2015-04-10 Медиммун, Ллк Способы культивирования клеток, размножения и очистки вирусов
FR2944292B1 (fr) * 2009-04-08 2013-08-23 Sanofi Pasteur Procede de purification du virus rabique
CN102947453A (zh) * 2010-01-28 2013-02-27 费城儿童医院 用于病毒载体纯化的可扩缩生产平台和用于基因治疗中的如此纯化的病毒载体
CN103189507A (zh) * 2010-10-27 2013-07-03 学校法人自治医科大学 用于向神经系统细胞导入基因的腺相关病毒粒子
PT2970948T (pt) * 2013-03-15 2019-03-20 Glaxosmithkline Biologicals Sa Métodos de purificação de arn
EP3055412B1 (en) * 2013-10-07 2020-09-02 Seqirus UK Limited Treated filter
EP3054007A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
IL259850B2 (en) 2015-12-11 2023-11-01 Univ Pennsylvania Gene therapy for treating familial hypercholesterolemia

Also Published As

Publication number Publication date
KR20220162834A (ko) 2022-12-08
RU2019104759A3 (pt) 2020-11-17
EP3488007A2 (en) 2019-05-29
SG11201900366QA (en) 2019-02-27
KR102695908B1 (ko) 2024-08-14
RU2768045C2 (ru) 2022-03-23
AU2017299779B2 (en) 2021-12-02
JP7153009B2 (ja) 2022-10-13
CA3031095A1 (en) 2018-01-25
KR20190045174A (ko) 2019-05-02
EP3488007B1 (en) 2023-12-20
RU2019104759A (ru) 2020-08-21
MY194198A (en) 2022-11-21
BR112019001146A2 (pt) 2019-04-30
DK3488007T3 (da) 2024-02-19
JP2019524101A (ja) 2019-09-05
ES2972859T3 (es) 2024-06-17
NZ750016A (en) 2025-09-26
IL264270A (en) 2019-02-28
AU2017299779A1 (en) 2019-01-31
CN109790549A (zh) 2019-05-21
EP3488007A4 (en) 2020-01-01
KR20240126073A (ko) 2024-08-20
WO2018017956A3 (en) 2018-03-08
FI3488007T3 (fi) 2024-03-19
IL301963A (en) 2023-06-01
WO2018017956A2 (en) 2018-01-25
MX2019000882A (es) 2019-08-12
US20190284576A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
PT3488007T (pt) Métodos escaláveis de recuperação elevada para produzir vetor viral adenoassociado recombinante (raav) de alto rendimento e vetores virais adenoassociados recombinantes (raav) produzidos pelos mesmos
IL246588A0 (en) High titer production of adeno-associated virus vectors
ZA201906240B (en) Constraining motion vector information derived by decoder-side motion vector derivation
GT201700214A (es) Producción de vectores adeno-asociados de gran tamaño
IL259595B1 (en) Gradual methods for the production of a recombinant adenovirus (aav) vector in a serum-free suspension cell culture system suitable for clinical use
CL2018002754A1 (es) Proceso de produccion de raav a base de columnas completamente escalable.
IL257819A (en) Recombinant vectors comprising 2a peptide
EP3221456A4 (en) Genome-modified recombinant adeno-associated virus vectors
IL254286B (en) Constructions of glut1-linked recombinant aav vectors and methods relating to restoration of glut1 expression
IL290258A (en) Transgenic Isfahan Viral Vector
IL280840A (en) Production methods for viral vectors
IL272655A (en) Recombinant adeno-associated vectors
GB2566572B (en) Methods for adeno-associated viral vector production
IL250475B (en) Antibodies against orai1, preparations containing them, polynucleotides encoding them, vectors and cells containing them and their uses
IL259964A (en) Adenovirus-associated vectors for the treatment of mucolipodosis type ii
GB201610448D0 (en) Adeno-associated viral vector system
GB201707261D0 (en) Adeno-associated viral vector system